Ceftazidime-avibactam for the treatment of carbapenem-resistant pathogens associated with healthcare-assosiated infections- a budget impact analysis in Argentina.

ALBAYTERO MN; MAC MULLEN M; PEIN C; ANSARI W; ELGART J; GLANCSZPIGEL M

Congreso; ISPOR 22th Annual European Congress; 2019

International Society for Pharmacoeconomics and outcomes research

OBJECTIVES: Our objective was to estimate the budgetary impact of adding Ceftazidime-Avibactam (CAZ-AVI) as therapy option in hospitalized patients in Argentina.METHODS: An excel-based budget impact model was adapted the context of Argentina to estimate budget impact of adding CAZ-AVI as therapy option in hospitalized patients with cUTI, cIAI, HAP/VAP from the payer perspective in 3-year time horizon. Number of eligible patients was estimated from Argentinian epidemiological data. Cure and adverse event rates were extracted from clinical trials. Hospital length of stay associated with treatment cures/failures was derived from clinical trials of CAZ-AVI. Costs of drugs were obtained from ANMAT's National Drug Vademecum. Costs of hospital stay were based on tariffs from social security institutions of Argentina. Costs were expressed in Argentine peso of November 2018. Current and future market shares were based on market research data and assumptions. Results are reported in terms of annual and per-patient budget impact. RESULTS: In Argentina, the estimated number of patients eligible for CAZ-AVI treated was 5,995, 6,388 and 6,791, in each year respectively. The estimated net budget impact for the introduction of CAZ-AVI was -$8,4 million; -$22,2 million and -$33,9 million for the 1 to 3 year respectively. The cumulative net budget impact was - $64,4 million, representing an impact of -1.4% compared to a scenario without CAZ-AVI, and mainly explained by the reduction in hospital bed days and hospitalization costs. The total cost per treated patient, prior to CAZ-AVI introduction, was estimated to be $240,186 [$276,720 (cIAI), $199,009 (cUTI), $291,646 (HAP/VAP)] and $236,824 [$262,463 (cIAI), $195,863 (cUTI), $299,056 (HAP/VAP)] after the introduction of CAZ-AVI.CONCLUSIONS: Our results suggest that the inclusion of CAZ-AVI as a therapeutic option in hospitalized patients with cUTI, cIAI, HAP/VAP could generate budgetary savings compared to current treatment options.